IBM wants to use its AI to help new antibody discoveries

IBM has announced a new collaboration with global research company Boehringer Ingelheim to use its AI foundation models to aid in the discovery of new antibody treatments.

Antibody treatments are the dominant weapon in the fight against a wide range of serious diseases, and produce far less side effects when compared to more traditional treatments.